CliniContact

We run AI in production across live trials every day, so here is the honest split: where it genuinely moves the needle, and where it is just decoration you should not trust with an enrollment target. New edition breaks down the three places AI actually earns its place, the four ways it burns people (fabricated eligibility, fake "AI matching," chatbot screeners, starved optimization), and the one rule underneath all of it. Everyone has the same models now. The ground truth going in is the difference. #ClinicalTrials #PatientRecruitment #ClinicalResearch #AI #ClinicalOperations

People assume good recruitment numbers come from better ads. They don't. We benchmark ours against the industry, not against our own last campaign, because that's the only comparison that actually means anything. Across 315 campaigns and 24 million impressions: - Cost per qualified lead runs about 60% below the healthcare benchmark - Cost per pre-qualified participant is roughly half the industry norm - Click-through and screener conversion both sit above the usual range Same protocols everyone else is running. What's different is the infrastructure underneath. We plan the recruitment around the protocol, the sites and the people you are trying to reach, then run it end to end, instead of handing over a folder of materials and wishing you luck. If your enrollment is behind, that gap is usually where it's hiding. Send us a protocol and we'll show you what it would look like on your study. #PatientRecruitment #ClinicalTrials #ClinicalResearch #ClinicalTrialRecruitment #ClinOps #RecruitmentInfrastructure

You shouldn’t need weeks of intake calls and endless revisions just to start recruiting. With Horizon, you instantly convert trial protocols into ready-to-submit IRB packages, live landing pages, and a complete media plan—all optimized to deliver more qualified candidates at a lower cost per enrollment.

The patients your trial needs most are often the ones advertising can't reach: underrepresented communities, rare-disease patients, and people who don't trust research. Bridge reaches them through the advocacy, community and clinical organisations they already trust. Those partners refer the people they support, and consent-first pre-screening hands your sites pre-qualified candidates. It's how you hit enrolment and the representation your sponsors and regulators now expect. Not passive matching. Real referrals from trusted sources. Book a call and we'll map it to your indication.

The patients your trial needs most are often the ones advertising can't reach: underrepresented communities, rare-disease patients, and people who don't trust research. Bridge reaches them through the advocacy, community and clinical organisations they already trust. Those partners refer the people they support, and consent-first pre-screening hands your sites pre-qualified candidates. It's how you hit enrolment and the representation your sponsors and regulators now expect. Not passive matching. Real referrals from trusted sources. Book a call and we'll map it to your indication.

The patients your trial needs most are often the ones advertising can't reach: underrepresented communities, rare-disease patients, and people who don't trust research. Bridge reaches them through the advocacy, community and clinical organisations they already trust. Those partners refer the people they support, and consent-first pre-screening hands your sites pre-qualified candidates. It's how you hit enrolment and the representation your sponsors and regulators now expect. Not passive matching. Real referrals from trusted sources. Book a call and we'll map it to your indication.